Description

Axsome Therapeutics Acquisition Play Signals A Bold Push Into Schizophrenia Market!

Axsome Therapeutics entered 2026 with a noticeably broader strategic agenda than it had just a few quarters earlier. After reporting strong 2025 commercial execution, including more than $639 million in annual revenue, over $507 million in AUVELITY sales, continued SUNOSI growth, and the early launch ramp of SYMBRAVO, the company signaled that it was no longer operating solely as a single-product growth story. That shift became more visible on April 1, 2026, when Axsome announced that it had acquired exclusive global rights from Takeda to balipodect, formerly TAK-063, a novel oral and selective PDE10A inhibitor. The asset has already completed a 164-patient Phase 2 proof-of-concept study in schizophrenia and has shown a favorable safety and tolerability profile across more than 360 individuals. Axsome plans to advance balipodect initially in schizophrenia and Tourette syndrome, with Phase 3-enabling activities for schizophrenia expected to begin in 2026.